Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Escalating Dose Phase IIa Study of L-Asparaginase Encapsulated in Erythrocytes (GRASPA®) in Association With Polychemotherapy During Induction Phase for Treatment of Elderly Patients With Acute Lymphoblastic Leukaemia (ALL), Aged 55 Years and Over, With Philadelphia Chromosome-negative (ALL Ph-)

NCT01523782 is registered in ClinicalTrials.gov with ERYtech Pharma as lead sponsor.

NCT NCT01523782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01523782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Escalating Dose Phase IIa Study of L-Asparaginase Encapsulated in Erythrocytes (GRASPA®) in Association With Polychemotherapy During Induction Phase for Treatment of Elderly Patients With Acute Lymphoblastic Leukaemia (ALL), Aged 55 Years and Over, With Philadelphia Chromosome-negative (ALL Ph-)
Lead sponsor
ERYtech Pharma
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2009
Completion date
October 31, 2012
Enrollment
30 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia